We report a case of Lichen Sclerosus in a 73-year-old man who had been treated for epilepsy with carbamazepine. Lichen sclerosus et atrophicus (LSA), also called lichen sclerosus (LS), is a chronic inflammatory cutaneous condition characterized by white plaques with epidermal atrophy and scarring. To date no cases of LSA has been linked to carbamazepine, although in a few cases lichenoid eruptions but without sclero-atrophy have been described after exposure to this drug. Therefore, to our knowledge, this is the first report of a Lichen sclerosus et atrophicus induced by carbamazepine
We report a case of Lichen sclerosus (LS) in a 73-year-old man who had been treated for epilepsy with carbamazepine. After six months of treatment, a generalized eruption involving trunk and limbs developed and multiple reddishbrown maculas characterized by a central atrophy occurred. Histological examination was consistent with the diagnosis of LS. Carbamazepine therapy is associated with cutaneous adverse reaction in up to 10% ofpatients and its administration may lead to an eruption of various skin lesions including lichenoid eruption; in-vitro lymphocyte transformation test (LTT) turned out positive to carbamazepine. Replacement of carbamazepine with oxcarbazepine and application of steroid therapy was effective in stopping the progression ofskin manifestation; There was no evidence of new lesions during 24 months of follow-up. This is the first report of LS induced by carbamazepine.
Lichen sclerosus et atrophicus (LSA), also called Lichen sclerosus, is a chronic inflammatory cutaneous condition characterized by white plaques with epidermal atrophy and scarring. It was first described by Hallopeau in 1887 (l) while its histology was analyzed by Darier in 1892 (2) . LSA usually occurs in the anogenital area but in some rare cases it can spread on other areas of the body. The etiopathogenesis of extragenital LSA is unknown, while for the anogenital form a viral etiology has been supposed. Recently, we had the opportunity to observe the eruption of an extragenital LSA in a 73-year-old man under treatment with antiepileptic drugs for a history of generalized tonic clonic seizures.
A 73-year-old man with no remarkable pathologic history, started having complex partial seizures at 63 years of age. The frequency of seizures increased from 72 years of age and he started to have episodes of generalized tonic clonic seizures. Magnetic Resonance Imaging (MRI) scans of the central nervous system showed vascular damage in fronto-parietal lobes. Electroencephalogram showed bilateral diffuse high waves (8-9 HZ). He underwent treatment with a number of antiepileptic drugs, including phenytoin and valproic acid, with no effective control of his epilepsy. Only when carbamazepine was administered as monotherapy 400 mg BID, a remission of his seizures was observed. After six months of carbamazepine treatment, a generalized skin eruption developed. Multiple red-brown macules with central atrophy (Fig. I a) were noticed first. The lesions involved the trunk and limbs without any symptoms other than mild itching. Histological examination of three skin biopsies showed atrophy of the epidermis with moderate vacuolization of epidermal basal cells and orthokeratotic hyperkeratosis, moderate sclerosis of the upper dermis with a Iymphohistiocytic band-like infiltrate beneath (Fig. 2) . Direct immunofluorescence did not show any deposit of IgM, IgA, IgG or C3. Clinical and histological features led to the diagnosis ofLichen sclerosus et atrophicus. Routine laboratory tests and immunological tests were in the normal range; Borrelia burgdoferi antibodies, antinuclear antibodies, anti-ECM 1, anti-BP-180 and anti-BP-230 were absent. On considering the possibility of a drug-induced eruption, carbamazepine was substituted by oxcarbazepine 600 mg BID. The discontinuation of carbamazepine was effective in stopping the progression of skin manifestation. During the second year follow-up only scattered white and atrophic lenticular lesions with a light brown perimeter were observed (Fig. I b) .
DISCUSSION
The disseminated and eruptive form ofextragenital LSA is very rare and poorly described in literature; moreover, to date, no cases of extragenital LSA have been related to the use of any drug. Diagnosis of LSA is based on clinical evaluation and histopathologic features that reveal vacuolization ofthe basal cell layer, upper dermal oedema, homogenization and sclerosis of collagen and lymphohistiocytic band-like infiltrates (3, 4) . With regard to its pathogenesis, a cytokine unbalancement could be considered (5-7). Regarding differential diagnosis, in our patient clinical and histopathologic features and the absence of collagen necrosis and blood vessel thrombosis excluded the diagnosis of Degos' disease; the diagnosis of lichen ruber planus was also excluded for the absence of the typical "wiped out" aspect of the basal layer and for the presence of sclerosis, while the diagnosis of guttate morfphea, was not considered for the absence of thickened collagen bundles infiltrating the entire dennis and extending into the subcutaneous fat (8) . However LSA and morphea may sometimes overlap with clinical and very similar histological features merging into one another. The pathogenesis of LSA is still unknown, although many studies support an immunologic etiology and a genetic susceptibility to LSA (9) . In our case the eruption of disseminated LSA appeared after administration of carbamazepine and disappeared after its discontinuation. Carbamazepine therapy is associated with cutaneous adverse reaction in up to 10% of patients and predisposition to these hypersensitive reactions has been linked to the human leukocyte antigen genotype (10) . Its administration may lead to many different eruptions, most frequently toxic epidermal necrolysis and Steven-Jonson syndrome; lichenoid eruptions are also described but rarely occur after prolonged use of the drug (11-16). The diagnosis of a skin eruption caused by a specific drug is difficult to achieve when considering the number of drugs that commonly a patient can take. In our case, replacement of carbamazepine with oxcarbazepine together with the application of topic steroid therapy was effective in stopping the progression of skin manifestation, leaving only scattered white and atrophic lenticular lesions. To date no cases of LSA have been linked to carbamazepine, although in a few cases lichenoid eruptions, but without sclero-atrophy, have been described after exposure to this drug. Therefore, to our knowledge, this is the first report ofa Lichen sclerosus et atrophicus induced by carbamazepine.
